Pfizer Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
11,101
18,523
20,123
19,663
19,685
Cost of Goods Sold (COGS) incl. D&A
6,287
11,661
11,757
12,428
11,908
Gross Income
4,814
6,862
8,367
7,235
7,778
SG&A Expense
2,362
3,878
4,252
3,922
3,306
EBIT
2,334
2,539
-
-
4,444
Unusual Expense
4
756
227
51
95
Non Operating Income/Expense
212
167
126
1,374
34
Interest Expense
11
15
14
20
8
Pretax Income
3,396
2,380
4,704
5,168
5,479
Income Tax
1,187
1,377
1,654
1,801
1,878
Consolidated Net Income
2,209
1,003
3,050
3,368
3,601
Net Income
2,209
1,003
3,050
3,368
3,601
Net Income After Extraordinaries
2,209
1,309
3,050
3,368
3,601
Net Income Available to Common
2,209
1,003
3,050
3,368
3,601
EPS (Basic)
74.01
15.26
66.66
73.61
78.70
Basic Shares Outstanding
30
46
46
46
46
EPS (Diluted)
74.01
15.26
66.66
73.61
78.70
Diluted Shares Outstanding
30
46
46
46
46
EBITDA
2,414
3,849
4,350
3,501
5,092
Other Operating Expense
118
446
325
427
28
Non-Operating Interest Income
857
445
576
877
983

About Pfizer

View Profile
Address
The Capital, 1802/1901
Mumbai Maharashtra 400051
India
Employees -
Website http://www.pfizerindia.com
Updated 09/14/2018
Pfizer Ltd. (India) engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. Its product offerings include treatment for depression, erectile dysfunction, high cholesterol, human immunodeficiency virus infection, hypertension, bacterial infections and systemic fungal infections, and other chronic therapeutic which includes pain, respiratory, vitamins or minerals, hospital anti-infectives, neurosciences, and cardiovascular. Its key products include Prevenar 13, Lyrica, Ativan, Viagra, Zosyn, Minipress XL, Meronem, Enbrel, Dolonex, Magnex, Amlogard, Trulimax, Daxid, Neksium, Becosules, Gelusil, Mucaine, Folvite, Autrin, Citralka, Corex Range, Anacin, and Anne French.